GlycoErase™ GALNT14 Knockout Glycoengineered Cell (CAT#: GLJF-0825-JF239)

Description	GlycoErase™ GALNT14 knockout glycoengineered cell eliminates GALNT14, a Golgi GalNAc-transferase that initiates mucin-type O-glycosylation. This model supports studies of mucin biosynthesis, signaling, and cancer biology.
Product Type	KO Cell Lines
Cell Line	As requested by the client.

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	GALNT14
Full Name	Polypeptide N-acetylgalactosaminyltransferase 14
Alternative Name	FLJ12691; GalNac-T14
Location	2p23.1
Gene ID	79623
Summary	Golgi protein that catalyzes the transfer of GalNAc to hydroxyl groups of serines and threonines in target peptides, initiating O-linked glycosylation.